Table 4. Combination chemotherapy studies for relapsed small-cell lung cancer.
| Author | Regimen | No. of pts | % of ref pts (%) | RR (%) | RR in ref pts (%) | MST (month) |
|---|---|---|---|---|---|---|
| Sculier | CAV | 61 | 75 | 21 | 5 | 6.2–7.5 |
| von Pawel | CAV | 104 | 20 | 18 | 5 | 6.2 |
| Roth | CAV | 41 | 32 | 12 | 8 | NM |
| Roth | PE | 59 | 46 | 22 | 15 | NM |
| Evans | PE | 78 | 50 | 55 | 28 | NM |
| Masuda | PE | 20 | NM | 50 | NM | 4.7 |
| Gridelli | CCNU/MTX | 33 | 100 | 21 | 21 | 4.0 |
| Faylona | PE/IFO | 46 | 41 | 55 | 50 | 6.8 |
| Kubota | CODE | 17 | 35 | 88 | 83 | 8.2 |
| Masuda | CPT-11/ETOP | 25 | 16 | 71 | 75 | 8.7 |
| Nakanishi | CPT-11/CDDP | 5 | 100 | 20 | 20 | NM |
| Domine | GEM/PTX | 31 | 58 | 50 | 40 | NM |
| Groen | CBDCA/PTX | 35 | 100 | 74 | 74 | 7.2 |
| Kosmas | CDDP/IFO/PTX | 33 | 61 | 73 | 70 | 6.5 |
Pts=patients; ref=refractory; RR=response rate; MST=median survival time; CAV=cyclophosphamide/doxorubicin/vincristine; PE=cisplatin/etoposide; CCNU= lomustine; MTX=methotrexate; IFO=ifosfamide; CODE=cisplatin/vincristine/doxorubicin/etoposide; CPT-11=irinotecan; ETOP=etoposide; CDDP=cisplatin; GEM=gemcitabine; PTX=paclitaxel; CBDCA=carboplatin; NM=not mentioned.